Trial Search Results

Long-Term Follow-up Safety Study of Human Central Nervous System Stem Cells in Subjects With Geographic Atrophy of Age-Related Macular Degeneration

This study is being done to determine the long-term safety and possible benefits of transplanted Human Central Nervous System Stem Cells (HuCNS-SC) for patients with Geographic Atrophy of Age-Related Macular Degeneration. This long-term follow-up study is limited to those individuals who received a transplant of HuCNS-SC cells into one of their eyes as part of the CL-N01-AMD study. No additional study product will be given in this 4-year long-term follow-up study.

Stanford is currently accepting patients for this trial.

Lead Sponsor:

StemCells, Inc.

Stanford Investigator(s):


  • Biological: Human Central Nervous System Stem Cells


Inclusion Criteria:

   - Must have completed Study CL-N01-AMD

   - Must be able to provide written informed consent prior to any study related procedures

   - Agree to comply in good faith with all conditions of the study and to attend all
   required study visits

Exclusion Criteria:

   - Inability to comply with study procedures or visits

   - Since enrolling in Study CL-N01-AMD, have entered, or are about to enter another
   investigational study that, in the opinion of the Principal Investigator (PI), might
   confound study interpretation.

   - Received off-study immunosuppressive agents in the lead-in study or are receiving any
   immunosuppressive agents since completing the lead-in study

Ages Eligible for Study

51 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Zayna Shaheen